AR012997A1 - Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. - Google Patents

Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.

Info

Publication number
AR012997A1
AR012997A1 ARP980102883A ARP980102883A AR012997A1 AR 012997 A1 AR012997 A1 AR 012997A1 AR P980102883 A ARP980102883 A AR P980102883A AR P980102883 A ARP980102883 A AR P980102883A AR 012997 A1 AR012997 A1 AR 012997A1
Authority
AR
Argentina
Prior art keywords
insulin
thiazolidin
amino
methyl
preparation
Prior art date
Application number
ARP980102883A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR012997A1 publication Critical patent/AR012997A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980102883A 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene. AR012997A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
AR012997A1 true AR012997A1 (es) 2000-11-22

Family

ID=10814527

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102883A AR012997A1 (es) 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
ARP980102886A AR015894A1 (es) 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980102886A AR015894A1 (es) 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos

Country Status (30)

Country Link
EP (1) EP0999837A1 (no)
JP (1) JP2002504138A (no)
KR (1) KR20010013843A (no)
CN (1) CN1133431C (no)
AP (1) AP1287A (no)
AR (2) AR012997A1 (no)
AU (1) AU8216398A (no)
BG (1) BG104059A (no)
BR (1) BR9810444A (no)
CA (1) CA2294141A1 (no)
CO (1) CO4940454A1 (no)
DZ (1) DZ2521A1 (no)
EA (1) EA004800B1 (no)
GB (1) GB9712866D0 (no)
HU (1) HUP0003260A3 (no)
ID (1) ID23951A (no)
IL (1) IL133143A0 (no)
IN (1) IN189723B (no)
MA (1) MA26511A1 (no)
NO (1) NO996265L (no)
OA (1) OA11517A (no)
PE (1) PE104499A1 (no)
PL (1) PL343123A1 (no)
SK (1) SK179399A3 (no)
TR (1) TR199903095T2 (no)
TW (1) TW587937B (no)
UA (1) UA70299C2 (no)
UY (1) UY25050A1 (no)
WO (1) WO1998057636A1 (no)
ZA (1) ZA985237B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (es) 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법

Also Published As

Publication number Publication date
TW587937B (en) 2004-05-21
CO4940454A1 (es) 2000-07-24
PL343123A1 (en) 2001-07-30
CN1260715A (zh) 2000-07-19
AU8216398A (en) 1999-01-04
SK179399A3 (en) 2000-11-07
EA004800B1 (ru) 2004-08-26
BR9810444A (pt) 2000-09-05
CA2294141A1 (en) 1998-12-23
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
NO996265D0 (no) 1999-12-17
ID23951A (id) 2000-06-08
NO996265L (no) 1999-12-17
UY25050A1 (es) 2000-09-29
BG104059A (en) 2000-10-31
WO1998057636A1 (en) 1998-12-23
IN189723B (no) 2003-04-19
OA11517A (en) 2004-02-04
HUP0003260A3 (en) 2001-12-28
MA26511A1 (fr) 2004-12-20
HUP0003260A2 (hu) 2001-05-28
ZA985237B (en) 2000-02-17
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
GB9712866D0 (en) 1997-08-20
DZ2521A1 (fr) 2003-02-08
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
IL133143A0 (en) 2001-03-19
UA70299C2 (en) 2004-10-15
TR199903095T2 (xx) 2000-08-21
EA200000042A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
GB0021784D0 (en) Novel pharmaceutical
ECSP034467A (es) Farmaceutico novedoso
PE20001239A1 (es) Composicion de un sensibilizador de insulina
EA200300004A1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
TH36758A (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
ECSP003434A (es) Nuevos compuestos
ECSP003435A (es) Nuevos compuestos
TH21154B (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน

Legal Events

Date Code Title Description
FA Abandonment or withdrawal